The European Medicines Agency (Ema) has initiated a rapid procedure continuous data review study on the antiviral drug remdesivir in relation to the treatment of Covid-19. It is a procedure that Ema uses to speed up the evaluation of a promising experimental drug during a public health emergency, such as the current pandemic. However, Ema points out, "it is still too early to draw conclusions about the drug's risk-benefit balance."
Coronavirus: Ema starts Remdesivir quick evaluation
5/2/2020, 1:26:49 PM
Study to speed up times, but 'it's early for conclusions' (ANSA)